Summary
UBS BiotechTop50 27Jun28 is an ETF - a fund traded on an exchange like a stock - run by UBS ZA. Positions inside: 42. The ten largest make up 74% of the fund.
- Yearly costs
- 0.50%
- Fund size
- ZAX 37.4M
- Positions
- 42
- Dividends
- Reinvested
- Running since
- 2023
What speaks for it
Nothing stands out in its favour.
What to watch
- The ten largest positions make up 74% of the fund, so its result rests on a few names.
- 100% of the fund is in one sector (Healthcare).
- Costs of 0.50% a year are above the middle of comparable funds (0.44%).
A fund has no Bulios Score and no Fair Price of its own - both are computed from the results of a single company. This page shows what is inside the fund and what it costs instead.
Price
- Avg. market cap
- $91.9B
- P/E
- 27.9x
- Forward P/E
- 21.6x
- P/S
- 1.4x
- P/B
- 0.3x
- P/FCF
- 3.0x
- EV/EBITDA
- 19.3x
- Dividend yield
- 0.65%
- ROIC
- 5.3%
- ROE
- 15.2%
- Gross margin
- 76.8%
- Operating margin
- 33.6%
- Net margin
- 257.2%
- Payout ratio
- 18.0%
- Net debt/EBITDA
- 0.7x
- Bulios Score
- 57
Weighted average of the 42 largest companies, which make up 100% of the fund. Banks and insurers are left out of the gross margin, the ROIC and the EBITDA figures.
What is inside?
Concentrated- 1 ARArgenx ARGX 15%
- 2 AMAmgen AMGN 12%
- 3 GIGilead Sciences GILD 9.8%
- 4 UCUCB UCB.BR 7.9%
- 5 VRVertex Pharmaceuticals VRTX 6.5%
- 6 GMGenmab A/S GMAB.CO 6.3%
- 7 MRMERCK MRK.DE 5.9%
- 8 MRModerna MRNA 4.3%
- 9 RERegeneron Pharmaceuticals REGN 4.1%
- 10 SOSwedish Orphan Biovitrum AB SOBI.ST 2.8%
Positions in the fund: 42. The ten largest make up 74% of it.
Composition as of Nov 7, 2026.
Where is it spread?
One sector dominatesBy sector
- Healthcare 100%
By country
- United States 51%
- Netherlands 16%
- Belgium 9.4%
- Denmark 7.7%
- Other countries 16%
By company size
- Mega cap 22%
- Large cap 70%
- Mid cap 7.2%
- Small cap 1.6%
By the company's market value: Mega cap from $200B, Large cap from $10B, Mid cap from $2B, Small cap from $300M, Micro cap below $300M.
Largest sector: Healthcare (100%). Largest country: United States (51%). Largest size group: Large cap (70%).
What does it cost me?
Expensive- A year from ZAX 10,000
- ZAX 50.00
- Over 20 years
- ZAX 2,416
From every ZAX 10,000 invested the fund takes ZAX 50.00 a year. You do not pay it separately - it is taken out of the fund's value. Over 20 years at 5% yearly growth that adds up to about ZAX 2,416.
Does it pay dividends?
No, it reinvestsThe fund pays nothing out. What its holdings earn stays inside and shows in the price.
Is it easy to buy and sell?
- Traded a day
- ZAX 1.04M
- Shares a day
- 68
On an average day about ZAX 1.04M of the fund changes hands.
How expensive are the companies inside?
Rather expensive- P/E of the companies inside
- 27.9
- Average Bulios Score
- 57 out of 100
Weight by Bulios Fair Price
- Undervalued 14%
- Fairly valued 37%
- Overvalued 49%
On average the companies inside trade for 27.9 times their yearly profit. By Fair Price, 49% of the rated weight comes out as overvalued.
Counted from its largest companies (42), which make up 100% of the fund. Each company counts by its weight. We use the metrics, the Bulios Score and the Fair Price of the companies themselves.
Similar funds
Funds that hold much of the same. The overlap says how much of their weight they share with this fund.
| Fund | Domicile | Size | 1-year change | Dividends | ||
|---|---|---|---|---|---|---|
IB IBB iShares Biotechnology ETF | United States | 0.44% | $11.1B | +35% | Pays out | 50% |
2B 2B70.DE iShares Nasdaq US Biotechnology UCITS ETF | Ireland | 0.35% | $954.9M | +43% | Reinvests | 50% |
BB BBH VanEck Biotech ETF | United States | 0.35% | $523.8M | +40% | Pays out | 50% |
SB SBIO.MI Invesco NASDAQ Biotech UCITS ETF | Ireland | 0.40% | $600.3M | +44% | Reinvests | 49% |
IB IBBQ Invesco Nasdaq Biotechnology ETF | United States | 0.19% | $84.9M | +36% | Pays out | 48% |
20 203780.KS MiraeAsset TIGER NASDAQ BIO ETF | South Korea | 0.30% | $77.5M | +24% | Reinvests | 48% |
